Potential Common Benchmark For Assessing New Diabetes Treatments

Published Jun 23, 2014
Basel, Switzerland - Many new products for type 2 diabetes mellitus (T2DM) will be launched in the coming years as a response to this ever-increasing world epidemic. Health technology assessment (HTA) agencies require cost-effectiveness studies of these agents, but no consistent set of utility data exists to act as a basis for these evaluations. Researchers from IMS Health and Swansea University aimed to report a set of utility values for T2DM and its complications to illustrate challenges in creating such a utility set. In the study “Review of Utility Values for Economic Modeling in Type 2 Diabetes,” published inValue in Health, the researchers reported a set of values that might act as a common benchmark for assessing new diabetes treatments. Several limitations were observed in selecting values for inclusion in economic evaluations including the use of different instruments to measure preferences, the variability in patient recruitment, heterogeneity in statistical analysis, large variability around some point estimates and lack of recent data. This highlights the need for further research and guidance for the selection of utilities for use in cost-effectiveness analyses. Adam Lloyd, MPhil, Senior Principal at IMS Health and co-author of the manuscript, said, “Evaluations of new diabetes therapy are inconsistent, because many estimates of patient outcomes are incomplete or do not meet the requirements of HTA agencies. Understanding long-term benefits is crucial to establishing whether new diabetes treatments offer good value for money. The use of a common set of inputs for different technologies might lead to greater consistency in evaluation of new therapies.”

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision-makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×